ATH 25.0% 0.5¢ alterity therapeutics limited

PBT2 Phase 1 study showed safety up to 800mg

  1. 136 Posts.
    I still believe that the FDA PCH is just a delay tactic (or CYA/"don't make waves" indecision) with safety in dogs as an excuse.  The phase 1 data for PBT2 showed a good safety profile up to a dosage of 800mg. Below is the statement and link from 2006.

    "
    May 15, 2006

    mce-anchorPrana Biotechnology announced pooled results from their phase I development program for PBT2 for the treatment of Alzheimer's disease (AD). These trials enrolled 55 young male volunteers and 32 older male and female volunteers; they were designed to investigate the safety, tolerability and pharmacokinetics of single and multiple oral doses of the drug. Preliminary data yielded a positive tolerability profile for doses up to 800 mg, with no significant differences in rates of adverse events (most common events included headache, gastrointestinal disturbance and somnolence). Maximum tolerated dose was not reached. Pharmacokinetic data indicated a rapid absorption profile, with peak plasma concentrations achieved within 3 hours of administration, a linear absorption profile following single doses of the drug, and little drug accumulation in multiple-dose regimens."

    Link: https://www.centerwatch.com/clinical-trials/results/new-therapies/nmt-details.aspx?CatID=11
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.5¢
Change
0.001(25.0%)
Mkt cap ! $26.19M
Open High Low Value Volume
0.5¢ 0.5¢ 0.5¢ $27.94K 6.050M

Buyers (Bids)

No. Vol. Price($)
46 57663299 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 56205001 43
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
0.5¢
  Change
0.001 ( 0.00 %)
Open High Low Volume
0.5¢ 0.5¢ 0.5¢ 20524121
Last updated 15.46pm 29/03/2024 ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.